• Title/Summary/Keyword: National center

Search Result 41,726, Processing Time 0.073 seconds

A Comprehensive and Comparative Review of Global Gastric Cancer Treatment Guidelines

  • Eom, Sang Soo;Choi, Wonyoung;Eom, Bang Wool;Park, Sin Hye;Kim, Soo Jin;Kim, Young Il;Yoon, Hong Man;Lee, Jong Yeul;Kim, Chan Gyoo;Kim, Hark Kyun;Kook, Myeong-Cherl;Choi, Il Ju;Kim, Young-Woo;Park, Young Iee;Ryu, Keun Won
    • Journal of Gastric Cancer
    • /
    • v.22 no.1
    • /
    • pp.3-23
    • /
    • 2022

  • Countries differ in their treatment expertise and research results regarding gastric cancer; hence, treatment guidelines are diverse based on evidence and medical situations. A comprehensive and comparative review of each country's guidelines is imperative to understand the similarities and differences among countries. We reviewed and compared five gastric cancer treatment guidelines in terms of endoscopic, surgical, perioperative, and palliative systemic treatment based on evidence levels and recommendation grades, as well as the postoperative follow-up strategies for each guideline. The Korean, Chinese, and European guidelines provided evidence and grading of the recommendations. The United States guidelines suggested categories for evidence and consensus. The Japanese guidelines suggested evidence and recommendations only for systemic treatment. The Korean and Japanese guidelines described endoscopic treatment, surgery, and lymphadenectomy in detail. The Chinese, United States, and European guidelines more intensively considered perioperative chemotherapy. In particular, the indications for chemotherapy and the regimens recommended by each guideline differed slightly. Considering their medical situations, each guideline had some diversity in terms of adopting evidence, which resulted in heterogeneous recommendations. This review will help medical personnel to comprehensively understand the diversity in gastric cancer treatment guidelines for each country in terms of evidence and recommendations.

  • https://doi.org/10.5230/jgc.2022.22.e10 인용 PDF KSCI

Proteomic and Immunological Identification of Diagnostic Antigens from Spirometra erinaceieuropaei Plerocercoid

  • Lu, Yan;Sun, Jia-Hui;Lu, Li-Li;Chen, Jia-Xu;Song, Peng;Ai, Lin;Cai, Yu-Chun;Li, Lan-Hua;Chen, Shao-Hong
    • Parasites, Hosts and Diseases
    • /
    • v.59 no.6
    • /
    • pp.615-623
    • /
    • 2021

  • Human sparganosis is a food-borne parasitic disease caused by the plerocercoids of Spirometra species. Clinical diagnosis of sparganosis is crucial for effective treatment, thus it is important to identify sensitive and specific antigens of plerocercoids. The aim of the current study was to identify and characterize the immunogenic proteins of Spirometra erinaceieuropaei plerocercoids that were recognized by patient sera. Crude soluble extract of the plerocercoids were separated using 2-dimensional gel electrophoresis coupled with immunoblot and mass spectrometry analysis. Based on immunoblotting patterns and mass spectrometry results, 8 antigenic proteins were identified from the plerocercoid. Among the proteins, cysteine protease protein might be developed as an antigen for diagnosis of sparganosis.

  • https://doi.org/10.3347/kjp.2021.59.6.615 인용 PDF KSCI

Clinical outcome of proton therapy for patients with chordomas

  • Youn, Sang Hee;Cho, Kwan Ho;Kim, Joo-Young;Ha, Boram;Lim, Young Kyung;Jeong, Jong Hwi;Lee, Sang Hyun;Yoo, Heon;Gwak, Ho-Shin;Shin, Sang Hoon;Hong, Eun Kyung;Kim, Han Kyu;Hong, Je Beom
    • Radiation Oncology Journal
    • /
    • v.36 no.3
    • /
    • pp.182-191
    • /
    • 2018

  • Purpose: To investigate the clinical outcome of proton therapy (PT) in patients with chordoma. Materials and Methods: Fifty-eight patients with chordoma treated with PT between June 2007 and December 2015 at the National Cancer Center, Korea, were retrospectively analyzed. The median total dose was 69.6 cobalt gray equivalent (CGE; range, 64.8 to 79.2 CGE). Local progression-free survival (LPFS), distant metastasis-free survival (DMFS), overall survival (OS), and disease-specific survival (DSS) rates were calculated by the Kaplan-Meier method. Results: With the median follow-up of 42.8 months (range, 4 to 174 months), the 5-year LPFS, DMFS, OS, and DSS rates were 87.9%, 86.7%, 88.3%, and 92.9%, respectively. The tumor location was associated with the patterns of failure: the LPFS rates were lower for cervical tumors (57.1%) than for non-cervical tumors (93.1%) (p = 0.02), and the DMFS rates were lower for sacral tumors (53.5%) than for non-sacral tumors (100%) (p = 0.001). The total dose was associated with both the LPFS rate and DMFS rate. The initial tumor size was associated with the DMFS rate, but was not associated with the LPFS rate. Three patients had grade 3 late toxicity with none ≥grade 4. Conclusion: PT is an effective and safe treatment in patients with chordomas. The tumor location was associated with the patterns of failure: local failure was common in cervical tumors, and distant failure was common in sacral tumors. Further refinement of PT, such as the utilization of intensity modulated PT for cervical tumors, is warranted to improve the outcome.

  • https://doi.org/10.3857/roj.2018.00164 인용 PDF KSCI